Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma Journal of Clinical Oncology (To appear)
2. 2011 High-dose chemotherapy with autologous hematopoietic stem cell transplantation in metastatic breast cancer: Overview of six randomized trials Journal of Clinical Oncology (To appear)
3. 2011 Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: A Phase I/II controlled, adaptively randomized study Journal of Clinical Oncology 29:294-302
4. 2011 High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials Journal of Clinical Oncology (To appear)
5. 2011 Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: A Bayesian meta-analysis. Cancer Investigation29:293-299
6. 2011 Guest Editorial. Comparing Survival Outcomes Across Centers—Biases Galore The Cancer Letter 37;11:7-10
7. 2011 Bayesian approaches for comparative effectiveness research Clinical Trials. (To appear
8. 2011 CALGB Pathology Committee Guidelines for Tissue Microarray Construction representing Multi-Center Prospective Clinical Trial Tissues. Journal of Clinical Oncology (To appear)
9. 2011 Pathologic complete response predicts recurrence-free survival more effectively by cancer subtype: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). (Submitted for publication
10. 2011 Reproducible research AmstatNews, January 2011 #403:16-17.
11. 2011 Decision Theory. In Encyclopedia of Biostatistics, Vol 2, 1109-1118 (1393-1402 in 2nd Ed New York: John Wiley & Sons. (Ed: Armitage P, Colton T.
12. 2011 Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). (Submitted for publication.)
13. 2011 . p53 expression in node positive breast cancer patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905) (Submitted for publication
14. 2011 Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size Journal of Biopharmaceutical Statistics (To appear)
15. 2010 Letter to the Editor: Bias and trials stopped early for benefit Journal of the American Medical Association 304:157
16. 2010 Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial . Journal of the American Medical Association 303:333-340.
17. 2010 Bayesian meta-analysis for comparative effectiveness and informing coverage decisions Medical Care 48:S137-S144.
18. 2010 Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer British Journal of Cancer. Jan 26
19. 2010 DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes Journal of Clinical Oncology 28:605-613.
20. 2010 . Adherence and persistence with oral adjuvant chemotherapy in older women with early stage breast cancer in CALGB 49907: Adherence Companion Study 60104. Journal of Clinical Oncology 28:2418-2422
21. 2010 A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug Clinical Trials 7:121-135
22. 2010 The design of Phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the National Cancer Institute Investigational Drug Steering Committee Clinical Cancer Research 16:1764-1769
23. 2010 Heterogeneity of response to chemotherapy and recurrence-free survival in neoadjuvant breast cancer: Results from the I-SPY TRIAL (CALGB 150007/150012; ACRIN 6657) (Submitted for publication
24. 2010 Adaptive dose-finding trial in Alzheimer’s disease. (Submitted for publication
25. 2010 Adaptive and Bayesian Approaches to Study Design. In Redesigning the Clinical Effectiveness Research Paradigm: Innovation and Practice-Based Approaches: Workshop Summary Institute of Medicine. Washington, DC: The National Academies Press. pp 174-180
26. 2010 Editorial. Adaptive clinical trials: The promise and the caution. Journal of Clinical Oncology 31:1423-1426
27. 2010 Editorial. The hazards of endpoints Journal of the National Cancer Institute 102:1376-1377
28. 2009 ). I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clinical Pharmacology & Therapeutics 86:97-100.
29. 2009 Letter to the Editor: Flawed inferences about screening mammography’s benefit based on observational data Journal of Clinical Oncology 27:639-640.
30. 2009 Effects of mammographic screening under different screening schedules: Model estimates of potential benefits and harms Annals of Internal Medicine 151:738-747.
31. 2009 NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. Journal of the National Comprehensive Cancer Network 7, Suppl 6:S1-S24.
32. 2009 High risk of recurrence for breast cancer Patients with HER2-positive node negative tumors 1 cm or smaller. Journal of Clinical Oncology 27:5700-5706.
33. 2009 Topoisomerase II&[alpha] amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin and 5FU (CAF) therapy in HER2 amplified, early breast cancer: Results of CALGB 8541/150013 Journal of Clinical Oncology 27:3430-3436
34. 2009 Using auxiliary information in clinical trials (Submitted for publication)
35. 2009 Genetic diversity among US sunflower inbreds and hybrids: Assessing probability of ancestry and potential for use in plant variety protection. Crop Science49:1295-1303
36. 2009 Bayesian Model Averaging in Meta-analysis: Vitamin E Supplementation and Mortality (with Discussion). Clinical Trials 6:28-41
37. 2009 Editorial. Adjuvant chemotherapy for breast cancer in older women. Women’s Health 5:453-457.
38. 2009 Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute101:1642-1649
39. 2009 Statistical Innovations in Cancer Research. In Cancer Medicine e.8. Ch 35, pp 446-463 London: BC Decker. (Ed: Holland J, Frei T et al.)
40. 2009 A dose-finding, “top-down,” Bayesian adaptive clinical trial design (Submitted for publication)
41. 2009 Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 6:205-216
42. 2009 Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine28:1680-1689
43. 2009 . Good practices for adaptive clinical trials. Drug Information Journal 43:539-556
44. 2009 Information on linked experiments (Submitted for publication)
45. 2009 Report of a Phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes Leukemia and Lymphoma 51:73-78.
46. 2009 Adjuvant chemotherapy with standard regimens is superior to capecitabine in older women with early stage breast cancer New England Journal of Medicine 360:2055-2065.
47. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840 Journal of Clinical Oncology 26:1642-1649
48. 2008 Letter to the Editor. The best graph may be no graph Chance 21(3):6
49. 2008 Commentary: The science of doping Nature 454:692-693.
50. 2008 Editorial. The screening mammography paradox: Better when found, perhaps better not to find British Journal of Cancer 98:1729-1730.
51. 2008 Commentary. Does mammography protect against death from breast cancer? OBG Management 20;1:25-26
52. 2008 Editorial Comment. Recommended changes to oncology clinical trial design: Revolution of evolution? European Journal of Cancer 44:8-11.
53. 2008 Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141. Cancer Treatment Reviews 34:223-230
54. 2008 Research issues affecting preoperative systemic therapy for operable breast cancer Journal of Clinical Oncology 26:806-813
55. 2008 Influence of activation state of ErbB-2 (HER2) on response to adjuvant cyclophosphamide/doxorubicin/fluorouracil for stage II, node-positive breast cancer: Cancer and Leukemia Group B Study 8541 Journal of Clinical Oncology 26:2364-2372
56. 2008 Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of Cancer and Leukemia Group B trials 9342 and 9840 . Journal of Clinical Oncology 26:2659-2665
57. 2008 A novel intra-operative molecular test for sentinel lymph node metastases in early stage breast cancer patients Journal of Clinical Oncology 26:3338-3345
58. 2008 Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Research and Treatment Feb 2008
59. 2008 Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M. D. Anderson Cancer Center experience. Cancer Epidemiology Biomarkers & Prevention 17:1096-1103
60. 2007 The difficult and ubiquitous problems of multiplicities. Pharmaceutical Statistics 6:155-160.
61. 2007 Optimal adaptive randomized designs for clinical trials. Biometrika 94:673-689.
62. 2007 A parallel phase I/II clinical trial design for combination therapies. Biometrics63:429-436
63. 2007 Simulation-based sequential Bayesian design. Journal of Statistical Planning and Inference Journal of Statistical Planning and Inference137:3140-3150
64. 2007 Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation. Clinical Trials4:5-14
65. 2007 HER2 and response to paclitaxel in node-positive breast cancer New England Journal of Medicine 357:1496-1506.
66. 2007 Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience Journal of Clinical Oncology 25:3699-370
67. 2007 Biomarker studies and other difficult inferential problems: Statistical caveats Seminars in Oncology 34(suppl 3):S17–S21
68. 2007 Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis Journal of Thoracic Oncology 2:397-401
69. 2007 COX-2 involvement in breast cancer metastasis to bone Oncogene 26:3789-3796
70. 2007 An intensive sequenced adjuvant chemotherapy regimen for breast cancer, a pilot study of the Cancer and Leukemia Group B Cancer Therapy 5:117-124.
71. 2007 Validity of models for prediction of BRCA1 and BRCA2 mutations Annals of Internal Medicine 147:441-450.
72. 2007 The decrease in breast-cancer incidence in 2003 in the United States. The New England Journal of Medicine 356:1670-1674
73. 2007 Commentary. In reply to “Does search for large genomic rearrangements impact on BRCAPRO carrier prediction?” Journal of Clinical Oncology 25:2634-2635
74. 2007 Commentary. The hazards of survival comparisons The Oncologist 12:510-511
75. 2007 Editorial: Breast cancer trends: A marriage between clinical trial evidence and epidemiology Journal of the National Cancer Institute 99:1139-1141
76. 2007 Commentary. Adaptive trial design Clinical Advances in Hematology & Oncology 5:522-524.
77. 2007 Guest Commentary. Pooling apples, oranges, lemons and limes makes a statistical fruit salad The Cancer Letter 33;42:5-6
78. 2006 Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 Breast Cancer Research 8:R66
79. 2006 Editorial. Bayesian Statistics Medical Decision Making 26:429-430.
80. 2006 Symmetrized percent change for treatment comparisons. The American Statistician60:27-31
81. 2006 Building and validating a prognostic index for biomarker studies. Disease Markers2:97-101.
82. 2006 Adaptive dose-response studies. Drug Information Journal40:451-461
83. 2006 A Bayesian decision-theoretic dose-finding trial. Decision Analysis3:197-207
84. 2006 MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation Molecular and Cellular Biology 26:7269-7282
85. 2006 Interpreting adjuvant breast cancer data in 2006 and beyond European Journal of Cancer. Supplements Vol 4, No. 13:17-22
86. 2006 Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of Cancer and Leukemia Breast Cancer Research and Treatment 100:301-308
87. 2006 Characterization of BRCA1 and BRCA2 mutations in a large United States sample Journal of Clinical Oncology 24(6):863-871
88. 2006 Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer Cancer 107:1459-66
89. 2006 Modeling the Impact of Treatment and Screening on Breast Cancer Mortality: A Bayesian Approach Monograph of the Journal of the National Cancer Institute Number 36:30-36
90. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer Journal of the American Medical Association 295:1658-1667.
91. 2006 Bayesian clinical trial Nature Reviews Drug Discovery 5:27-36
92. 2005 Using molecular sizes of simple sequence repeats versus discrete binned data in assessing probability of ancestry: Application to maize hybrids. Genetics 170:365-374.
93. 2005 Relationship between Bayesian and frequentist sample size determination The American Statistician 59:79-87.
94. 2005 Review of Bayesian Approaches to Clinical Trials and Health-Care Evaluation by DJ Spiegelhalter, KR Abrams and JP Myles John Wiley & Sons, Ltd 2004. Statistics in Medicine 24
95. 2005 Commentary. Clinical Trials—Is the Bayesian approach ready for primetime? Stroke 36:1621-1622
96. 2005 Obituary. Seymour Geisser Journal of the Royal Statistical Society: Series A 168:245.
97. 2005 The Bayesian principle: can we adapt? Stroke 36:1623-1624.
98. 2005 Letter to the Editor. Breast cancer heterogeneity may explain peaks in recurrence International Journal of Surgery 3:287
99. 2005 Efficient Dose-Response Finding Strategies for Acute Neuroscience Populations. In Handbook of Neuroemergency Clinical Trials. Ch 9, pp 179-204 New York: Elsevier. (Ed: Alves WM, Skolnick BE.)
100. 2005 Primary hyperparathyroidism and osteosarcoma: Examination of a large cohort identifies three cases of fibroblastic osteosarcoma Journal of Bone and Mineral Research 20:1562-8.
101. 2005 CpG island methylation is a poor predicts prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: Results of a phase III randomized study Blood 106:790.
102. 2005 Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials Journal of the National Cancer Institute 97:1195-1203.
103. 2005 Adjuvant chemotherapy in older and younger women with lymph node–positive breast cancer Journal of the American Medical Association 293:1073-1081
104. 2005 Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer Journal of Clinical Oncology 23:8331-8339
105. 2005 Effect of screening and adjuvant therapy on mortality from breast cancer . New England Journal of Medicine 353:1784-1792
106. 2005 Bayesian predictions of final outcomes: regulatory approval of a spinal implant Clinical Trials 2:325-333.
107. 2005 Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin-containing chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer Journal of Clinical Oncology 23:3676-3685
108. 2005 Comparison of HER2 status by fluorescent in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients Journal of Clinical Oncology 23:4287-4297
109. 2005 Designing Clinical Trials in Hematopoietic Stem Cell Transplantation (Submitted for publication
110. 2005 One- and Two-armed Bandit Problems. Methods and Applications of Statistics in the Life and Health Sciences New York: John Wiley & Sons. (Ed: Balakrishnan N.
111. 2005 Statistical Innovations in Cancer Research. In Cancer Medicine e.7. Ch 29, pp 411-425 London: BC Decker. (Ed: Holland J, Frei T et al.)
112. 2005 Introduction to Bayesian methods III: Use and interpretation of Bayesian tools in design and analysis. Clinical Trials2:295-300
113. 2005 Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. Genetic Epidemiology29:141-154
114. 2005 A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD. BMC Genetics6:S138
115. 2005 The past is the future: innovative designs in acute stroke therapy trials. Stroke 36:1341-1347
116. 2004 Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analysis Archives of Internal Medicine 164:40-44
117. 2004 Commentary. Screening mammography: a decision analysis. International Journal of Epidemiology 33:68.
118. 2004 A randomized comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage 1, estrogen receptor positive carcinoma of the breast: Results of CALGB study 9343 New England Journal of Medicine 351:971-977.
119. 2004 HER2/neu disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy International Journal of Radiation Oncology*Biology*Physics 59:1337-1342
120. 2004 Breast Cancer. Chapter 6 in Textbook of Clinical Trials New York: John Wiley & Sons (Ed: Machin D, Day S.) (Republished in 2006, pp. 49-61.)
121. 2004 Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Journal of Clinical Oncology 22:2061-8.
122. 2004 Inferences about Testosterone Abuse among Athletes Chance 17(2):5-8
123. 2004 Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: A phase II study of the Cancer and Leukemia Group B (CALGB 9041). Investigational New Drugs 22:83-89
124. 2004 Bayesian survival analysis with nonproportional hazards: Metanalysis of pravastatin-aspirin. Journal of the American Statistical Association99:36-44
125. 2004 Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixed model. Biometrics 60:418-426.
126. 2004 Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science19:175-187
127. 2003 Clinical Trial Design Gynecologic Oncology 88:S114-S116
128. 2003 Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based chemotherapy: A Study by the Cancer and Leukemia Group B Journal of Clinical Oncology 21:1825-1835
129. 2003 Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. Journal of Clinical Oncology 21:1819-1824
130. 2003 Designs for Phase II and Phase III Cancer Drug Studies. Chapter 26 in Handbook of Anticancer Drug Development. pp. 379-392 . Lippincott Williams & Wilkins (Ed: Budman D.)
131. 2003 Bayesian dose-response meta-analysis comparing LDL-C lowering of rosuvastatin and atorvastatin. American Heart Journal.145:1036-1045
132. 2003 The difficult and ubiquitous problems of multiplicities International Chinese Statistical Association Bulletin, Jul, 42-45
133. 2003 Statistical Innovations in Cancer Research. In Cancer Medicine e.6. Ch 33, pp 465-478 London: BC Decker. (Ed: Holland J, Frei T et al.)
134. 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup C9741/Cancer and Leukemia Group B Trial 9741 . Journal of Clinical Oncology 21:1431-1439
135. 2003 Choosing sample size for a clinical trial using decision analysis. Biometrika 90:923-936
136. 2003 Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia Journal of Clinical Oncology 21:1722-1727
137. 2003 Assessing probability of ancestry using simple sequence repeat profiles: Applications to maize inbred lines and soybean varieties. Genetics 165:331-342
138. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer Journal of Clinical Oncology 21:976-983
139. 2002 Adaptive Clinical Trials and Bayesian Statistics (with Discussion). Pharmaceutical Report 9(2):1-11. American Statistical Association.
140. 2002 Revision of the American Joint Committee on Cancer staging system for breast cancer. Journal of Clinical Oncology.20:3628-3636. (Reprinted as Staging System for Breast Cancer: Revisions for the 6th Edition of the AJCC Cancer Staging Manual In The Surgical Clinics of North America. Breast Cancer: New Concepts in Management. 83 (4) Aug 2003:803-819. Philadelphia PA, W.B. Saunders Company. Ed: Jatoi I, Singletary SE.)
141. 2002 The Utility of Mammography for Women 40 to 50 Years of Age (Con) In Progress in Oncology 2002 233-259. Sudbury MA, Jones and Bartlett. (Ed: DeVita VT, Hellman S, Rosenberg SA.)
142. 2002 Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genetic Testing 6:93-105
143. 2002 Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with survival, toxicity and dosing weight in patients with primary breast cancer Clinical Cancer Research 8:698-705
144. 2002 BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes Journal of Clinical Oncology 20:2701-12
145. 2002 Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial . Clinical Cancer Research 8:1073-1079
146. 2002 High-dose vs standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology 20:743-750
147. 2002 Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant CAF chemotherapy: A Cancer and Leukemia Group B Correlative Science Study from Protocol 8541/8869 Journal of Clinical Oncology 20:732-742
148. 2002 Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58:264-272
149. 2002 Assessing probability of ancestry using simple sequence repeat profiles: Applications to maize hybrids and inbreds. Genetics161:813-824
150. 2001 Cancer genomics: Promises and complexities Clinical Cancer Research 7:2159-2167
151. 2001 Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer Bone Marrow Transplantation 27:1245-1253
152. 2001 Adaptive Bayesian Designs for Dose-Ranging Drug Trials. Case Studies in Bayesian StatisticsV 99-181. New York: Springer-Verlag. (Ed: Gatsonis C, Kass RE, Carlin B, Carriquiry A, Gelman A, Verdinelli I, West M.)
153. 2001 Sequential Statistical Methods. International Encyclopedia of Social and Behavioral Sciences 20:13922-13927. Oxford, UK: Elsevier. (Ed: Smelser NJ, Baltes PB.)
154. 2001 Circulating HER2/c-neu extra cellular domain (ECD/HER2) as a prognostic factor in patients with metastatic breast cancer: Cancer & Leukemia Group B study 8662 Clinical Cancer Research 7:2703-2711
155. 2001 Editorial. Role of population-based studies in assessing genetic cancer risk Journal of the National Cancer Institute 93:1188-1189
156. 2001 Overconfident physician opinion on the effectiveness of BRCA1 risk reduction measures Breast Cancer Research 3.2:E001. http://breast-cancer-research.com/content/3/2/E001
157. 2001 Monitoring a clinical trial conducted under the new FDA regulations allowing a waiver of prospective informed consent: The DCLHb traumatic shock efficacy trial Annals of Emergency Medicine 38.4: 397-404
158. 2000 Plasma D-dimer levels in operable breast cancer patients correlate with extent of disease involvement Journal of Clinical Oncology 18:600-608.
159. 2000 Association of angiogenesis in lymph node metastases with outcome of breast cancer. Journal of the National Cancer Institute 92:486-492
160. 2000 ). HER-2/neu and p53 expression vs tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer. Journal of Clinical Oncology 18:3471-3479.
161. 2000 The cost-effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes Disease Management and Clinical Outcomes Winter:15-24.
162. 2000 Genetic susceptibility and survival: Application to breast cancer. Journal of the American Statistical Association95:28-42
163. 2000 Meta-Analysis: Past and Present Challenges. Meta-Analysis in Medicine and Health Policy1-28. New York: Marcel Dekker. (Ed: Stangl DK, Berry DA.)
164. 2000 Meta-Analysis in Medicine and Health Policy. 398 pp, New York: Marcel Dekker
165. 2000 Review of Pharmaceutical Experimental Design by GA Lewis, D Mathieu, R Phan-Tan-Luu Journal of the American Statistical Association 95:339
166. 1999 Modeling risk of breast cancer and decisions about genetic testing. Case Studies in Bayesian Statistics IV 415-436. (Ed: Carlin B, Carriquiry A, Gatsonis C, Gelman A, Kass RE, Verdinelli I, West M.)
167. 1999 Validating Bayesian prediction models: A case study in genetic susceptibility to breast cancer. Case Studies in Bayesian Statistics IV321-338. (Ed: Carlin B, Carriquiry A, Gatsonis C, Gelman A, Kass RE, Verdinelli I, West M.)
168. 1999 Response to Cameron-Leonard Journal of the National Cancer Institute 91:728-729
169. 1999 Response to Hryniuk Journal of the National Cancer Institute 91:1425.
170. 1999 Cytochrome P450c17 gene (CYP17) polymorphism is associated with increased breast cancer risk (Submitted for publication.)
171. 1999 Is axillary lymph node dissection indicated for early stage breast cancer?—A decision analysis Journal of Clinical Oncology 17:1465-1473
172. 1999 Testing for BRCA1 breast-ovarian cancer susceptibility gene: A decision analysis. . Medical Decision Making 18:365-375.
173. 1999 A dose-response trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B phase III study 8741 Journal of Clinical Oncology 17:64-73
174. 1999 Attitudes, knowledge and risk perceptions of women with breast cancer considering testing for BRCA1 and BRCA2 Journal of Clinical Oncology 17:1040-1046.
175. 1999 BRCA1 and BRCA2 mutation carrier status and survival after breast cancer (Submitted for publication.)
176. 1999 Response to Robin Vollmer Journal of the National Cancer Institute 91:286-287
177. 1999 Statistical Models in Epidemiology, the Environment and Clinical Trials 274 pp, New York: Springer-Verlag
178. 1999 Cost-effectiveness of treatment of early stage endometrial cancer Gynecologic Oncology 74:208-216.
179. 1999 Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose chemotherapy with autologous stem-cell support support. Journal of Clinical Oncology 17:3064-3074
180. 1999 . Response to Kopans-Halpern. Journal of the National Cancer Institute 91:383-384.
181. 1999 The safety and efficacy of using a single agent or phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study: CALGB 8642 . Journal of Clinical Oncology 17:1397-1406.
182. 1999 Bayesian perspectives on multiple comparisons. Journal of Statistical Planning and Inference82:215-227
183. 1998 The Detection and Significance of Tumor Cell Contamination of the Bone Marrow Proceedings of the Ninth Symposium of Bone and Marrow Transplantation.
184. 1998 Advances in breast cancer genetics . Recent Advances in Laboratory Medicine 81:183-186
185. 1998 Expression of Tie-2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis British Journal of Cancer 77:51-56
186. 1998 Benefits and risks of screening mammography for women in their forties: A statistical appraisal Journal of the National Cancer Institute 90:1431-1439
187. 1998 erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer Journal of the National Cancer Institute 90:1346-1360.
188. 1998 Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer Journal of the National Cancer Institute 90:1205-1211
189. 1998 Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is primarily due to a marked reduction in veno-occlusive disease of the liver Bone Marrow Transplantation 21:117-122
190. 1998 Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. The American Journal of Human Genetics62:145-158
191. 1998 Bayesian statistics in medicine: Where we are and where we should be going. Sankhya 60:176-195
192. 1998 Assessing the benefits of testing for breast cancer susceptibility genes: A decision analysis. Breast Disease 10(1,2): 115-125
193. 1998 The effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history Journal of the National Cancer Institute 90:1824-1829
194. 1998 Screening mammography for women in their forties Breast Disease 10(3,4): 23-32.
195. 1998 Bayesian multiple comparisons using Dirichlet process priors. Journal of the American Statistical Association 93:1130-1139
196. 1998 Overestimation of hereditary breast cancer risk Annals of Surgery 228:375-384.
197. 1998 Secondary myelodysplasia and acute leukemia in breast cancer patients following autologous bone marrow transplant Journal of Clinical Oncology 16:1008-1012
198. 1998 Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer . Cancer Chemotherapy and Pharmacology 42:497-503
199. 1998 Genetic testing in breast cancer cooperative clinical trials: Barriers and opportunities Cancer Therapeutics 1:95-99
200. 1997 The significance of tumor contamination in the bone marrow from high risk primary breast cancer patients treated with high dose chemotherapy and hematopoietic support. Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation 3:91-97.
201. 1997 High-dose chemotherapy for high-risk primary breast cancer. In: Salmon SE, ed. Adjuvant Therapy of Cancer VIII, Philadelphia: Lippincott-Raven. 117 – 122
202. 1997 Relation of glutathione S-transferase a and m isoforms to response to therapy in human breast cancer Clinical Cancer Research 3:661-667.
203. 1997 Response to Daniel Schaid Journal of the National Cancer Institute 89:1634.
204. 1997 Review of Quantification and the Quest for Medical Certainty by JR Matthews (Princeton University Press, 1995). The Quarterly Review of Biology 72:359-360.
205. 1997 Teaching elementary Bayesian statistics with real applications in science (with discussion). The American Statistician 51:241-274
206. 1997 Bandit problems with infinitely many arms. The Annals of Statistics 25:2103-2116.
207. 1997 Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute 89:227-238.
208. 1997 Race is not an independent prognostic factor for women receiving adjuvant chemotherapy for stage II breast cancer: An analysis based on CALGB 8541 The Cancer Journal of Scientific American 3:107-112
209. 1997 Breast cancer screening for women ages 40-49 Journal of the National Cancer Institute 89:1015-1026. (Reprinted in Monograph of the Journal of the National Cancer Institute (1997) 22:vii-xii.)
210. 1996 A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral blood progenitor cells in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology 37:561-569
211. 1996 Statistics: A Bayesian Perspective 518 pp, Belmont, California: Duxbury Press
212. 1996 Bayesian Analysis in Statistics and Econometrics: Essays in Honor of Arnold Zellner 577 pp, New York: Wiley-Interscience
213. 1996 Bayesian Biostatistics 681 pp, New York: Marcel Dekker.
214. 1996 Editorial. When Is a Confirmatory Randomized Clinical Trial Needed? Journal of the National Cancer Institute 89:1206-1207
215. 1996 Statistics: Theory and Methods (Second Edition) 702 pp, Belmont, California: Duxbury Press
216. 1996 Bayesian Methods in Health-Related Research. Bayesian Biostatistics. 1-66. New York: Marcel Dekker. (Ed: Berry DA, Stangl DK.)
217. 1995 Discussion of "Elicitation, Monitoring, and Analysis for an AIDS Clinical Trial" by Carlin BP, Chaloner KM, Louis TA, Rhame FS Case Studies in Bayesian Statistics II. 79-85. New York: Springer-Verlag. (Ed: Gatsonis C, Hodges JS, Kass RE, Singpurwalla ND.)
218. 1995 High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B Breast Cancer Research and Treatment 36:35-40
219. 1995 Editorial comments on "Parametric Survival Analysis of Adjuvant Therapy for Stage II Breast Cancer" by Gamel JW, et al In Breast Diseases: A Year Book Quarterly 6:201. Chicago: Mosby. (Ed: Balch CM.)
220. 1995 Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Statistics in Medicine14:231-246
221. 1995 A Bayesian group sequential design for a multiple arm randomized clinical trial. Statistics in Medicine 14:381-394
222. 1995 Optimal designs for clinical trials in stages. In Adaptive Designs. Hayward, CA: Institute of Mathematical Statistics Monograph Series25:124-138. (Ed: Flournoy N, Rosenberger WF.)
223. 1995 Scientific Inference and Predictions; Multiplicities and Convincing Stories: A Case Study in Breast Cancer Therapy (with discussion). Bayesian Statistics Bayesian Statistics 5:45-67. Oxford, England: Oxford University Press. (Ed: Bernardo JM, Berger JO, Dawid AP, Smith AFM.)
224. 1995 Decision Analysis and Bayesian Methods in Clinical Trials. In Recent Advances Clinical Trial Design and Analysis125-154. New York: Kluwer Press. (Ed: Thall P.)
225. 1995 Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869 Cytometry 22:297-306
226. 1995 Amonafide: An active agent in the treatment of previously untreated advanced breast cancer: A Cancer and Leukemia Group B study (CALGB 8642) Clinical Cancer Research 1:699-704.
227. 1994 DNA, Statistics and the Simpson Case. Chance 7 4):9-12
228. 1994 Bayesian group sequential clinical trial designs based on a quadratic loss function Proceedings of the Section on Bayesian Statistical Science of the American Statistical Association 23-28.
229. 1994 c-erbB-2 expression predicts response to adjuvant therapy in women with node positive early breast cancer. New England Journal of Medicine 330:1260-1266.
230. 1994 Overexpression of the p53 and HER-2/neu proteins as prognostic markers in early breast cancer Annals of Surgery 219:332-341
231. 1994 Group sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs. Journal of the American Statistical Association89:1528-1534
232. 1994 Decision making during a phase III randomized controlled trial. Controlled Clinical Trials 15:360-379
233. 1994 Applications of Lindley information measure to the design of clinical experiments. Aspects of Uncertainty: A Tribute to DV Lindley329-348. Chichester, England: Wiley. (Ed: Freeman PR, Smith AFM.)
234. 1994 Stopping a clinical trial early: Frequentist and Bayesian approaches applied to a CALGB trial non-small cell lung cancer. Statistics in Medicine non-small cell lung cancer. Statistics in Medicine13:1313-1327
235. 1994 Discussion of "DNA Fingerprinting: A Review of the Controversy" by Roeder K Statistical Science 9:222-278.
236. 1994 Discussion of "Bayesian Approaches to Randomized Trials" by Spiegelhalter DJ, Freedman LS, Parmar MKB Journal of the Royal Statistical Society, Series B 157:357-416
237. 1993 Review of Multi-armed Bandit Allocation Indices by JC Gittins Metrika 40:134-136
238. 1993 Editorial. Power of chronobiologic pilots—A statistician's opinion Chronobiologica 20:213
239. 1993 A case for Bayesianism clinical trials (with discussion). Statistics in Medicine 12:1377-1404
240. 1993 Using historical controls clinical trials: Application to ECMO. Statistical Decision Theory and Related Topics V 141-156. New York: Springer-Verlag. (Ed: Berger JO, Gupta S.)
241. 1993 Clinical research in the critical care environment Critical Care Medicine. 21 (suppl):S400-S402
242. 1992 Endoscopic release of the carpal tunnel: A randomized prospective multicenter study. The Journal of Hand Surgery 17:987-995
243. 1992 Transparent Polyurethane Film as a Catheter Dressing. Journal of the American Medical Association 268 (18
244. 1992 Statistical Issues DNA Identification. In DNA on Trial: Genetic Identification and Criminal Justice DNA Identification. In DNA on Trial: Genetic Identification and Criminal Justice91-108. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. (Ed: Billings PR.)
245. 1992 Public Health Decision Making: A Sequential Vaccine Trial (with discussion). Bayesian Statistics Bayesian Statistics4:79-96. Oxford, England: Oxford University Press. (Ed: Bernardo JM, Berger JO, Dawid AP, Smith AFM.)
246. 1992 Statistical inferences in crime investigations using deoxyribonucleic acid profiling (Read paper, with discussion). Journal of the Royal Statistical Society, Series C 41:499-53141:499-531
247. 1991 Probability of Paternity. The Use of Statistics in Forensic Science150-156. New York: Ellis Horwood Limited. (Ed: Aitken CGG, Stoney DA.)
248. 1991 Inferences using DNA profiling in forensic identification and paternity cases (with discussion). Statistical Science 6:175-205
249. 1991 Bayesian methodology in Phase III trials. Drug Information Journal25:345-368
250. 1991 Worth of perfect information in Bernoulli bandits. Advances in Applied Probability23:1-23
251. 1991 Bayesian methods for monitoring survival in congestive heart failure. In Biopharmaceutical Sequential Statistical Applications 201-217 New York: Marcel Dekker. (Ed: Peace KE.)
252. 1991 More on "DNA Fingerprinting". Chance 3 (4).
253. 1991 Experimental design for drug development: A Bayesian approach. Journal of Biopharmaceutical Statistics 1:81-101
254. 1991 Review of Probability Models by Ross SM. Journal of Official Statistics 7:133
255. 1990 DNA fingerprinting: Can it prove guilt? Chance 3 (3):15-25
256. 1990 Bounded limits and statistical inference in chronobiometry. Chronobiology: Its Role in Clinical Medicine, General Biology, and Agriculture, Part B
257. 1990 Variability of different methods for measurement of ECG interval temporal variation The Journal of Electrocardiology 22 (Suppl):125-126
258. 1990 Comments on Kempthorne (1989). The American Statistician 44:187
259. 1990 Invited paper: A Bayesian Approach to Metaanalysis and Multicenter Trials Proceedings of the Pharmaceutical Section of the American Statistical Association 1-10
260. 1990 Subgroup analyses. Biometrics47:1227-1230.
261. 1990 A comparison of antiarrhythmic drugs for suppression of ventricular ectopic depolarizations: A meta-analysis American Heart Journal 120:340-353
262. 1989 Basic Principles in Designing and Analyzing Clinical Studies Statistical Methodology in the Pharmaceutical Sciences 1-55. New York: Marcel Dekker
263. 1989 The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide and verapamil: Effects on cardiac function and drug clearance Clinical Pharmacology and Therapeutics 46:26-32
264. 1989 Ethics and ECMO: Comment on a paper by Ware. Statistical Science4:306-310.
265. 1989 Identification of drug interactions by meta-analysis of premarketing trials: The effect of smoking on the pharmacokinetics and dosage requirement for flecainide acetate Clinical Pharmacology and Therapeutics 46:1-8
266. 1989 Significant Statistics. Natural History 6
267. 1989 Invited paper: Challenge of the Future of Statisticians in the Pharmaceutical Field: Academic Perspective Proceedings of the Pharmaceutical Section of the American Statistical Association 217-219
268. 1989 Invited paper: Inferential Aspects of Adaptive Allocation Rules. Proceedings of the Pharmaceutical Section of the American Statistical Association 1-8.
269. 1989 Monitoring accumulating data in a clinical trial. Biometrics 45:1197-1211
270. 1989 Statistical Methodology in the Pharmaceutical Sciences 580 pp, New York: Marcel Dekker
271. 1988 Discussion of "Bayesian Approaches to Clinical Trials" by Spiegelhalter DJ, Freedman LS In Bayesian Statistics 3:243-259. Oxford, England: Oxford University Press. (Ed: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM.)
272. 1988 Discussion of "Bayesian Paleoethnobotany" by Kadane JB, Hastorf CA In Bayesian Statistics 3:243-259. Oxford, England: Oxford University Press. (Ed: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM.
273. 1988 Responses to Letters to the Editor The American Statistician 42:89
274. 1988 Responses to Letters to the Editor The American Scientist 76. (Various issues.)
275. 1988 Invited paper: Inferences Concerning Adverse Experiences in Pharmaceutical Trials. Proceedings of the Pharmaceutical Section of the American Statistical Association 15-17
276. 1988 One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach. Biometrics44:219-227
277. 1988 Comparisons, Multiple Tests, and Data Dredging: A Bayesian Perspective (with discussion). Bayesian Statistics 3:79-94. Oxford, England: Oxford University Press. (Ed: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM.)
278. 1988 Statistical analysis and the illusion of objectivity. The American Scientist 76:159-165
279. 1988 Optimality of myopic stopping times with geometric discounting. Journal of Applied Probability 25:437-443.
280. 1988 The Relevance of Stopping Rules in Statistical Inference (with discussion). Statistical Decision Theory and Related Topics IV1:29-72. New York: Springer-Verlag. (Ed: Berger JO, Gupta S.)
281. 1988 Interim analysis in clinical research. Cancer Investigation5:469-477
282. 1987 Statistical inference, clinical trials, and pharmaceutical company decisions. The Statistician 36:181-189
283. 1987 Odds Are Against the Twins, but They Aren't Overwhelming (Commentary Star Tribune (Oct. 16) Minneapolis, Minnesota
284. 1987 The pharmacodynamic and pharmacokinetic interaction of flecainide acetate with propranolol: Effects on cardiac function and drug clearance. European Journal of Clinical Pharmacology33:97-99
285. 1987 Interim analysis in clinical trials: The role of the likelihood principle. The American Statistician 41:117-122
286. 1987 Logarithmic transformations in ANOVA. Biometrics 43:439-456
287. 1986 ). Inferences in Cases of Disputed Paternity. Statistics and the Law 353-382. New York: Wiley. (Ed: DeGroot MH, Fienberg SE, Kadane JK.)
288. 1986 . Review of Introduction to Stochastic Dynamic Programming by Ross SM Journal of the American Statistical Association 81:573.
289. 1986 Discrete search with directional information. Operations Research34:470-477
290. 1986 Invited paper: Marshall/MacIntosh LAD vs. Nonaugmented Controls Proceedings from the Symposium on Prosthetic Augmentation of Autogenous Grafts II 54-74. St. Paul, Minn.:3M
291. 1986 The effects of single dose atenolol, labetalol, and propranolol on cardiac and vascular function. Clinical Pharmacology and Therapeutics40:268-273
292. 1986 Pharmacodynamics and side effects of flecainide acetate. Clinical Pharmacology and Therapeutics 40:101-107
293. 1985 Bayesian nonparametric bandits. The Annals of Statistics13:1523-1534
294. 1985 The probability of a field goal: Rating kickers. The American Statistician39:152-155
295. 1985 Optimal designs for two-stage clinical trials with dichotomous responses. Statistics in Medicine 4:497-508
296. 1985 One- and Two-armed Bandit Problems. Encyclopedia of Statistical Sciences, Vol. VI 418-422. New York: John Wiley & Sons. (Ed: Kotz S, Johnson NL.)
297. 1985 Interim analysis in clinical trials: Classical vs. Bayesian approaches. Statistics in Medicine4:521-526
298. 1985 Bandit Problems: Sequential Allocation of Experiments 275 pp. London: Chapman-Hall
299. 1984 The application of second-order polynomial equations to the study of pharmacodynamic interactions: The effect of flecainide acetate and propranolol on cardiac output and vascular resistance. The Journal of Pharmacology and Experimental Therapeutics231:286-290
300. 1984 Some Gambling Problems with Nonintuitive Solutions. Invited paper: Proceedings of the Seventh Conference in Probability Theory41-49. Utrecht, Holland: VNU-Science Press. (Ed: Iosifescu M.)
301. 1984 Assessing differential drug effect. Biometrics40:1109-1115
302. 1983 Statistics of Disputed Paternity Cases. Invited paper: Proceedings of the Social Statistics Section of the American Statistical Association 131-138
303. 1983 Review of Bayesian Statistics, edited by Bernardo JM, DeGroot MH, Lindley DV, Smith AFM Technometrics 25:206-207.
304. 1983 Flecainide versus quinidine for treatment of chronic ventricular arrhythmias: A multicenter trial. Circulation67:1117-1123
305. 1983 Bandit Problems with Random Discounting. In Mathematical Learning Models—Theory and Algorithms 12-25. New York, Springer-Verlag. (Ed: Herkenrath U, Kalin D, Vogel W.)
306. 1983 Regression analysis applied to PVC histories: A statistical procedure for evaluating antiarrhythmic drug efficacy. Statistics in Medicine2:331-343
307. 1983 Maximizing the length of a success run for many-armed bandits. Stochastic Processes and Their Applications 15:317-325
308. 1982 Optimal stopping regions with islands and peninsulas. The Annals of Statistics10:634-636
309. 1982 Review of Statistical Decision Theory by Berger JO Technometrics 24:80-82
310. 1981 Bernoulli two-armed bandits with geometric termination. Stochastic Processes and Their Applications11:35-45
311. 1981 Discussion of "Randomized allocation of treatments in sequential experiments" by Bather JA Journal of the Royal Statistical Society, Series B 43:289.
312. 1981 Elementary Statistics 530 pp, New York: Macmillan
313. 1980 Two-armed bandits with a goal, II. Dependent arms. Advances in Applied Probability12:958-971
314. 1980 Two-armed bandits with a goal, I. One arm known. Advances in Applied Probability12:775-798
315. 1980 Statistical inference and the design of clinical trials. Biomedicine 32:4-7
316. 1979 Empirical Bayes estimation of a binomial parameter via mixtures of Dirichlet processes. The Annals of Statistics 7:558-568
317. 1979 Bernoulli one-armed bandits—arbitrary discount sequences. The Annals of Statistics7:1086-1105
318. 1979 Detecting trends in arrangements of ordered objects: A likelihood approach. The Scandinavian Journal of Statistics6:169-174
319. 1978 Probabilities of winning a certain carnival game. The American Statistician32 126-129
320. 1978 Introduction to Probability and Statistics, 4th ed. 365 pp, New York New York: Macmillan
321. 1978 Modified two-armed bandit strategies for certain clinical trials. Journal of the American Statistical Association 73:339-345
322. 1978 Review of Probability and Statistics by DeGroot MH Journal of the American Statistical Association 73:218-219
323. 1977 A modern statistical approach to model assessment. Political Development and Change: A Policy Approach 462-486. New York: Free Press. (Ed: Brewer G, Brunner R.
324. 1977 A note on inverse sampling procedures for selecting the best binomial population. The Annals of Statistics5:235-236
325. 1974 Red-and-black with unknown win probability. The Annals of Statistics2:602-608.
326. 1974 Optimal sampling schemes for estimating system reliability by testing components—I: Fixed sample sizes. Journal of the American Statistical Association61:485-491
327. 1974 A class of optimal stopping problems for sampling without replacement. Biometrika61:361-368
328. 1973 An improved procedure for selecting the better of two Bernoulli populations. Journal of the American Statistical Association68:979-984
329. 1972 Letter to the Editor The American Statistician 26:47
330. 1972 Subjective Inference The American Statistician 26:195
331. 1972 A Bernoulli two-armed bandit. The Annals of Mathematical Statistics43:871-897


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.